ABSTRACT: Aplyronine A (ApA) is an antitumor marine macrolide that induces an protein−protein interaction (PPI) between actin and tubulin. The C1−C9 macrolactone part including the C7 N,N,O-trimethylserine (TMSer) ester is important for its highly potent activities. To develop new antitumor PPI inducers, four aplyronine analogues were synthesized, which bear the C1−C9 macrolactone part with 0−2 TMSer ester(s) and the C24−C34 actin-binding side chain. Despite exhibiting potent actin-depolymerizing activity comparable to that of ApA, these analogues did not show potent cytotoxicity or depolymerize microtubules. Molecular modeling studies suggested that the whole macrolactone moiety of aplyronines was important to fix the conformation of the C7 TMSer ester moiety, while the linear C1−C9 part was insufficient. Still, our study newly proposed that fixed conformations of the C7 or C9 TMSer esters in aplyronines that protrude from the actin surface are important for binding to tubulin and inhibit microtubule dynamics.
■ INTRODUCTION
The manipulation of new protein−protein interactions (PPIs) by natural products and related small bioactive compounds has become an important issue in the fields of basic life sciences and drug discovery. 1 The use of PPI-stabilizing or -inhibiting scaffolds has important implications for simplified mimetic design and provides new insights into ways to design molecules that tether proteins using different binding surfaces. 2 Among a small number of natural products that simultaneously interact with more than one biomacromolecule, aplyronine A (ApA, 1), 3−5 a 24-membered antitumor macrolide isolated from the sea hare Aplysia kurodai, promotes a unique PPI between actin and tubulin, two of the major cytoskeletal proteins (Figure 1 ). ApA was originally characterized as an actin-targeting agent that depolymerizes fibrous actin (F-actin) and inhibits the polymerization of actin by forming a 1:1 complex with the monomeric globular molecule (G-actin). 6 While it also exhibits potent cytotoxicity against HeLa S3, a human cervical carcinoma cell line at an IC 50 of 10 pM, this concentration is much lower than that needed for disassembly of the actin cytoskeleton (∼100 nM). We recently showed that ApA forms a 1:1:1 heterotrimeric complex with actin and tubulin, in association with the synergistic binding of actin to tubulin, and inhibits tubulin polymerization. 7 This synergistic binding effect of the actin−ApA complex toward tubulin has been supported through the use of gel-permeation HPLC, surface plasmon resonance analysis, 8 and photolabeling and affinity pulldown experiments.
9,10 Several tubulin-targeting agents have been widely used in cancer chemotherapy. To the best of our knowledge, however, ApA is the first microtubule inhibitor that has been shown to have a PPI-inducing effect between actin and tubulin to inhibit microtubule dynamics. 2 The structure of ApA can be divided into two characteristic parts: the C1−C23 macrolactone with an N,N,O-trimethylserine (TMSer) ester and the C24−C34 side chainwith an N,Ndimethylalanine (DMAla) ester, and the latter is important for actin-depolymerizing activity.
11 X-ray analysis of the actin− ApA complex revealed that ApA intercalates into the hydrophobic cleft between subdomains 1 and 3 of actin by using the side-chain moiety of 1. 12 The crystallographic structures of complexes of actin with several macrolides that have side chain(s) similar to those of ApA have also been reported, such as kabiramide C, 13 sphinxolide B, 14 reidispongiolides A and C, 14 and swinholide A, 15 all of which bind to actin at the same site. In fact, a synthetic ApA analogue of the C21−C34 side-chain 4 specifically binds to actin at the same site as aplyronines and moderately depolymerizes F-actin. 16 Meanwhile, as for the macrolactone moiety, the presence of the C7 TMSer ester in 1 is essential for the potent activity of ApA because aplyronine C (ApC, 3), which lacks the C7 TMSer ester, does not bind to tubulin and its cytotoxicity is 1700 times weaker than that of 1.
9b Thus, it has been suggested that the positively charged C7 TMSer ester that protrudes from the actin−ApA complex might generate a unique tubulin-binding site, which drives the interaction with tubulin α/β-heterodimer. 7 ApA exhibits potent antitumor activities in vivo against P388 leukemia, Lewis lung carcinoma, and Ehrlich carcinoma. 3a To develop new PPI modulators with potent biological activities, two ApA analogues have been synthesized, which bear the whole macrolactone moiety of ApA and the side-chain parts of mycalolide B or swinholide A. 17 Both of these "hybrid" molecules exhibited potent actin-depolymerizing activity, and the latter showed potent cytotoxicity and induced potent PPI between actin and tubulin, as with ApA. Meanwhile, there have been few studies on the structural modification and simplification of the macrolactone moiety of aplyronines. To better understand the binding modes and antitumor mechanism of ApA and to develop new analogues that retain the potent PPI-inducing activity of ApA between actin and tubulin as new drug leads, we examined here the simplification of the macrolactone part of aplyronines.
■ RESULTS AND DISCUSSION
To get perspectives for the design of structurally simplified aplyronine analogues, molecular modeling studies were performed. Aplyronine B (ApB, 2) is a minute congener of ApA isolated from A. kurodai, in which the TMSer ester is migrated from C7 to C9. It is less cytotoxic than ApA but 7-to 8-fold more cytotoxic than ApC. 3a,4c While the crystallographic structures of complexes of ApB or ApC with actin have not been reported, they are expected to bind to actin, similar to ApA and related actin-depolymerizing macrolides. Thus, conformational searches for ApA and ApB bound to actin were performed using the Amber12:EHT force-field, in which both actin and the C24−C34 side chainwere fixed. Among the ten and two lowest-energy conformers of ApA and ApB obtained within 30 kJ/mol, those with the lowest energies were almost dominant (97.8 and 99.9% occupations, respectively) ( Figure 2 ). In the most stable conformer of ApA, the macrolide part (C1−C23) including the C7 TMSer ester moiety almost completely overlapped than those in the actin−ApA complex [PDB: 1WUA] [root-mean-square deviation (rmsd) 0.477 Å for all of the C, O, and N atoms of the macrolactone part]. It was expected that our modeling studies are applicable to precisely predict the conformations of natural and synthetic ApA analogues on actin. In the most stable conformer of ApB, the orientation of the macrolide part was far different from that in the actin−ApA complex, while its C9 TMSer ester protruded from the surface of actin, like the C7 TMSer ester of ApA. While it is still unclear whether ApB interferes with microtubule dynamics in association with actin like ApA, we assumed that some spatial and conformational variance of the TMSer ester might be allowed for PPI-inducing activity and potent cytotoxicity of aplyronines.
Previous structure−activity relationship (SAR) studies showed that the functional groups of ApA that are important for cytotoxicity are the C7 TMSer ester, the C9 hydroxy group, and a conjugated diene moiety on the macrolactone ring. Based on the modeling studies as mentioned above, we designed structurally simplified ApA analogue 5, in which the C1−C9 macrolactone part was connected with the C24−C34 side chainvia an ester bond ( Figure 1 ). We expected that the conjugated diene moiety in 5 would partially fix the conformation of the linear C1−C9 part, which makes its C7 TMSer ester direct to the desired position on the complex with actin. For reference, we planned to synthesize ApC analogue 6, which lacks the C7 TMSer ester of 5. We were concerned that 5 might not show potent PPI-inducing activity if the C7 TMSer ester is tightly attached to the actin surface. For such an undesired interaction to occur, bis-C7,C9-TMSer analogue 7 was designed, in which either at least the C7 or C9 TMSer ester would be apart from the surface of actin and interact with tubulin. In addition, to simplify the synthetic pathway, symmetrical bis-C7,C7′-TMSer analogue 8 was designed. All four aplyronine analogues could be prepared via the esterification of C1−C9 (or C7) unsaturated carboxylic acids with the common C23−C34 primary alcohol, followed by regioselective esterification of the TMSer group.
First, the C23−C34 side-chain part 16 was synthesized (Scheme 1). A known primary alcohol 9
18 prepared from (S)-3-hydroxy-2-methylpropionate was converted into the phenyl tetrazole (PT) sulfide with aryl disulfide/ n Bu 3 P, and subsequent oxidation with meta-chloroperbenzoic acid (m-CPBA) yielded PT−sulfone 10. Julia−Kocienski olefination 19 of 10 with sterically hindered aldehyde 11 4c and lithium hexamethyldisilazide (LHMDS) as a base in 1,2-dimethoxyethane (DME) 20 at temperatures of −55°C to room temperature afforded an olefin quantitatively (E/Z = 1:2). Simultaneous catalytic hydrogenation of the olefin and hydrogenolysis of the benzyl group using palladium(II) hydroxide on carbon resulted in the epimerization of C29 secondary alcohol. Thus, removal of the benzyl group with calcium-mediated Birch reduction and selective protection of the primary alcohol with a tert-butyldiphenylsilyl (TBDPS) group gave silyl ether 12. Catalytic hydrogenation of the olefin with Pd(OH) 2 on carbon, condensation with N,N-dimethyl-Lalanine, acidic hydrolysis of the C34 methyl acetal, and reduction of the hemiacetal using sodium borohydride afforded diol 13. Trityl group (Tr) protection of the primary alcohol and subsequent acetylation of the remaining C31 secondary alcohol gave acetate 14. Removal of the Tr group with formic acid in ether and oxidation of the primary alcohol with Dess− Martin periodinane 21 provided aldehyde 15. Finally, dehydrating condensation with N-methylformamide under acidic conditions and selective deprotection of the TBDPS group with ammonium fluoride furnished compound 16.
We next set out to synthesize three kinds of unsaturated carboxylic acids, which correspond to the C1−C9 or C1−C7 macrolactone part of aplyronines (Scheme 2). Homoallylic alcohol 17, 22 prepared from methyl (S)-3-hydroxy-2-methylpropionate using Hosomi−Sakurai allylation 23 as a key step, was converted to the diol by calcium-mediated Birch reduction. Subsequent acetonide protection of the 1,3-diol, Lemieux−Johnson oxidation of the terminal olefin, 24 and Horner−Wadsworth−Emmons reaction of the aldehyde with triethyl 4-phosphonocrotonate gave conjugated ester 18 with high stereoselectivity (4E/4Z = 10:1). Next, removal of the acetonide group under acidic conditions and selective protection of the primary alcohol with a TBDPS group gave mono-silyl ether 19. To prepare the ApA and ApC analogues 5 and 6 having or lacking the C7 TMSer ester, the C7 hydroxy group was protected with a methylthiomethyl (MTM) ether using dimethylsulfoxide (DMSO)/Ac 2 O/AcOH 25 or a tertbutyldimethylsilyl (TBS) ether. Hydrolysis of the ethyl esters ; (e) TBDPSCl, imidazole, DMF; (f) H 2 , Pd(OH) 2 /C, NaHCO 3 , EtOH; (g) N,N-dimethyl-L-alanine, EDC·HCl, DMAP, CH 2 Cl 2 ; (h) aq HCl, DME; (i) NaBH 4 under mild conditions using lithium hydroxide provided MTM-and TBS-protected unsaturated carboxylic acids 20 and 21. Similarly, another unsaturated carboxylic acid 23 having the bis-C7,C7′-TBS ether was synthesized from a known aldehyde 22 26 in 2 steps. With the side-chain and the linear C1−C9 (or C1−C7) macrolactone parts in hand, we examined the synthesis of aplyronine analogues 5−8 (Scheme 3). Condensation of the side-chain part 16 with carboxylic acid 20 using the procedure of Yamaguchi et al. 27 and removal of the MTM group by silver(I) nitrate yielded C7-hydroxy ester 24. Condensation of the secondary alcohol with N,N,O-trimethyl-L-serine and removal of the two silyl groups at C9 and C25 by the hydrogen fluoride−pyridine (HF·py) complex furnished ApA analogue 5. Also, direct removal of the two silyl groups in 24 yielded the corresponding ApC analogue 6 (32% in 5 steps from 19). Because of the low efficiency of the protection/ deprotection sequence using an MTM group, we also examined the condensation of 16 with the TBS-protected carboxylic acid 21. Subsequent removal of three silyl groups by HF·py complex at once afforded 6 in a more efficient manner (57% in 4 steps from 19). To our delight, chemoselective condensation at the C7 and C9 hydroxy groups in 6 with N,N,O-trimethyl-L-serine selectively provided bis-C7,C9-TMSer analogue 7, due to the structural hindrance at the C25 secondary alcohol. Finally, condensation of 16 with carboxylic acid 23 followed by the removal of three TBS groups gave triol 25, which was converted to bis-C7,C7′-TMSer analogue 8 as in the case with 7.
The biological activities of aplyronine analogues 5−8 were compared to those of natural ApA. For the in vitro F-actin sedimentation assay, an ultracentrifugation method was used, which is applicable for various actin-targeting agents and their fluorescent, photoreactive, and other derivatives.
9a, 28 The amount of F-actin (3 μM as monomer) in the precipitate (P) fraction was reduced by treatment with ApA in a dosedependent manner, and the protein bands were observed almost entirely in the supernatant (S) fraction at 5 μM, as with the G-actin (Figure 3a , far left, without Mg 2+ ). The EC 50 of ApA was 1.4 μM against 3 μM actin, which well coincided with those by a pyrene-labeled (pyrenyl) actin method (EC 50 1.3− 1.6 μM against 3−3.7 μM actin) 17 (Table 1) . Similarly, four aplyronine analogues 5−8 showed significant actin-depolymerizing activities, with EC 50 values of <5, <5, 2.1, and 1.3 μM against 3 μM actin, respectively, all of which were stronger than that of the C21−C34 side-chain analogue 4 (EC 50 7.9 μM against 3.7 μM actin, 20% residual activity of ApA).
16a
The PPI-inducing effects of aplyronine analogues between actin and tubulin were then examined by using a similar ultracentrifugation method. ApA (8.5 μM) specifically induced microtubule disassembly in the presence of actin (3 μM for monomers), and both of these proteins were dominantly detected in the S fraction (Figure 3b) . 8 Meanwhile, even at the highest available concentrations of ApA analogue 5 (27 μM) and bis-TMSer analogues 7 and 8 (85 μM each), most of the tubulin remained in the P fractions (ca. 96.8, 87.8, and 92.1%), while substantial actin was moved to the S fractions (ca. 66.9, 84.9, and 87.0%). These results suggested that compounds 5, 7, and 8 scarcely depolymerized microtubules synergistically with actin, similar to ApC. 7 As for cytotoxicity, four aplyronine analogues 5−8 all moderately inhibited the proliferation of HeLa S3, a human cervical carcinoma cell line (IC 50 1.1−1.9 μM) ( Table 1) . ApA analogue 5 was >13 times more cytotoxic than side-chain analogue 4, but 140 000-and 82-fold less cytotoxic than natural ApA and ApC, respectively. Furthermore, the cytotoxicities of compounds 5 and 6 were almost the same, which did not reflect the significant difference in the cytotoxicity of natural aplyronines. Previous studies showed that fluorescent aplyronine derivatives, for example, those conjugated with tetramethylrhodamine, are rapidly accumulated in the cytoplasm and cause rapid disassembly of the actin cytoskeleton in HeLa S3 cells, and thus natural aplyronines are highly cell-permeable. 28 However, it is likely that the cellpermeability of the four aplyronine analogues 5−8 is very low, as is that of the side-chain analogue 4, and the presence of positively charged TMSer and/or DMAla esters contributed little to their potent cytotoxicities. As a result, an ApA analogue 5 and bis-TMSer analogues 7 and 8 were unable to induce PPIs between actin and tubulin either in vitro or in cells. Still, however, the C1−C9 part in 5−8 might contribute to the potentiation of actin-depolymerizing activity and cytotoxicity of the C24−C34 side chainby enhancing the interaction with actin.
To consider why synthetic aplyronine analogues 5, 7, and 8 did not show significant PPI-inducing effects between actin and tubulin, molecular modeling studies were performed, in which both actin and the C24−C34 side chainwere fixed. Among the 17 lowest-energy conformers of 5 on actin obtained within 30 kJ/mol, that with the lowest energy accounted for a relatively high proportion (90.3% occupation) (Figure 4a ). However, the C1−C9 moiety of the most stable conformer of 5 had a far different conformation from that of ApA (rmsd 4.978 Å for all of the C, O, and N atoms of the C1−C9 part) due to the hydrogen bond between the methoxy group of the C7 TMSer ester and the carboxyl group of Asp25 (Figure 4b ), which was not observed in the original actin−ApA complex. In contrast, the C1−C9 moiety of the fourth stable conformer of 5 (ΔE +11.9 kJ/mol, 0.7% occupation) well coincided with that of ApA (rmsd 0.865 Å for all of the C, O, and N atoms of the C1−C9 part) (Figure 4c) , in which the C7 TMSer ester protruded from the actin surface, and the C9 hydroxy group directly interacted with the carboxyl group of Glu334 (Figure 4d) . Due to such a low proportion of the desired conformation on actin, however, ApA analogue 5 might be unable to interact with tubulin.
As for the bis-TMSer analogues 7 and 8, 46 and 54 lowestenergy conformers were obtained within 30 kJ/mol. The most stable conformers of 7 and 8 accounted for 89.1 and 71.9%, respectively, and both of their C7 TMSer esters interacted with Asp25, as with 5. While the additional C9 TMSer ester in 7 did not attach to the actin surface, its orientation was far different from those of ApA and ApB models (Figure 4e ). In addition, the second C7′ TMSer ester in 8 was still tightly bound to actin (Figure 4f ). These undesired major conformations of bisTMSer esters might explain why 7 and 8 did not exhibit significant PPI-inducing activities.
We considered again the conformation of ApA on actin, and the C13 methoxy group interacts with Arg147 via water molecules in addition to direct interaction of the C9 hydroxy group with Glu334 (Figure 4g ). While the conformation of the macrolactone moiety of ApB on actin was far different from that of ApA, its C13 methoxy group was close to Arg147 based on the similar hydrogen bonds with that of the actin−ApA complex (Figure 2b ). These results suggested that such multiple hydrogen bonds might be essential to restrict the conformation of the macrolactone moiety of aplyronines and that the linear C1−C9 macrolactone part was insufficient to enable the C7 or C9 TMSer esters to protrude from the actin surface to bind to tubulin, like natural ApA and ApB, and interfere with microtubule dynamics in association with actin. 
■ CONCLUSIONS
For the development of new molecules to regulate PPI between actin and tubulin, four aplyronine analogues, which bear the C1−C9 macrolactone part with 0−2 TMSer ester(s) and the C24−C34 actin-binding side chain, were synthesized with the aid of molecular modeling studies. Despite their actindepolymerizing activity comparable to that of ApA, these aplyronine analogues did not show significant PPI-inducing effects. Molecular modeling studies suggested that the whole C1−C23 macrolactone moiety of aplyronines was important to fix the conformation of the C7 TMSer ester to interact with tubulin. As a result, our synthesized analogues were oversimplified, and the linear C1−C9 macrolactone and the C24− C34 side-chain parts of aplyronines were insufficient for both tubulin recruitment and potent cytotoxicity. Still, our SAR and molecular modeling studies newly proposed that the C7 or C9 TMSer esters in aplyronines A and B that protruded from the actin surface are important for their potent activities, which are superior to those of other agents that merely target actin, from the viewpoint of antitumor drug discovery and development. Actin is the most abundant protein in eukaryotic cells and is essential for the regulation of various cellular functions, such as cell division and tumor migration. It is possible that actintargeting agents interact with various cellular targets via unknown PPIs. 2 Thus, the results of this study have potential in the design and development of newly classified PPI modulators as pharmacological tools and therapeutic agents. Further investigations on the mechanisms of action of aplyronines and the development of new PPI-regulating molecules inspired by diverse actin-targeting natural products are currently underway.
■ EXPERIMENTAL SECTIONS
General Information. All chemicals were obtained commercially unless otherwise noted. Organic solvents and reagents for moisture-sensitive reactions were distilled by the standard procedure. Anhydrous CH 2 Cl 2 , tetrahydrofuran (THF), DME, benzene, pyridine, DMSO, and N,N-dimethylformamide (DMF) were obtained commercially. Column chromatography was performed using silica gel BW-820MH or FL60D (75−200 or 45−75 μm, Fuji Silysia Co., Aichi, Japan) or a Yamazen preparative silica gel (40 μm). All moisture-sensitive reactions were performed under an atmosphere of argon or nitrogen, and the starting materials were azeotropically dried with benzene before use. Merck precoated silica gel 60 F254 plates were used for thin layer chromatography.
Spectroscopic Analysis. 1 H and 13 C nuclear magnetic resonance (NMR) spectra were recorded on a Bruker BioSpin AVANCE 600 spectrometer (600 MHz for Cell Culture and Cytotoxicity Assay. HeLa S3 cells (suspension culture-adapted human cervical carcinoma cell line, ATCC CCL-2.2) were cultured in Eagle's minimal essential medium supplemented with fetal bovine serum (10%) in a humidified atmosphere containing CO 2 (5%), as described previously.
7,10 ApA (1) was isolated from the sea hare A. kurodai, according to published methods. 3, 5 For bioassays, ApA and its synthetic derivatives were stored in DMSO at 1−10 mM. The cytotoxicity of ApA and its derivatives was measured by the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide (MTT) method. 29 In brief, HeLa S3 cells were seeded at 2 × 10 3 cells per well in 96-well plates. After incubation overnight at 37°C, aplyronines (1 pM to 1 mM) were added, and the cells were incubated for 96 h at 37°C. A 1.4 mg/mL MTT solution in phosphate buffer saline (50 μL) was added to the cells. After 4 h, the culture medium was removed and the formazan product was dissolved in DMSO (150 μL). Optical density at 540 nm was measured with a TECAN microplate reader (Infinite 200 Pro). All assays were performed in duplicate to confirm reproducibility.
In Vitro F-Actin Sedimentation Assay. 9a, 28 To a solution of rabbit skeletal muscle actin (3 μM, cytoskeleton) in G-buffer [2 mM Tris·HCl (pH 8.0), 0.2 mM CaCl 2 , 0.2 mM ATP, 0.5 mM 2-mercaptoethanol] (500 μL) was added a 0.15 M solution of MgCl 2 (3.3 μL), and the mixture was stirred at 25°C for 1 h. To the polymerized F-actin solution (200 μL) were added samples (1 μL in DMSO), and the resulting mixtures were stirred at 25°C for 30 min and then ultracentrifuged (150 000g, 22°C, 1 h). Aliquots of the supernatants and precipitates (re-dissolved in G-buffer) were mixed with the same amount of 2× SDS buffer (Sigma) and boiled at 95°C for 5 min. SDS-PAGE was performed by using a precast 10% polyacrylamide gel (ATTO), and the gels were stained with a Quick-CBB kit (Wako). Densitometry of CBBstained proteins was performed using ImageJ software.
Microtubule Sedimentation Assay. 8 A solution of 6 μM tubulin (as a heterodimer) in modified RB buffer [100 mM PIPES·Na (pH 6.9), 1 mM EGTA, 2 mM MgCl 2 ] was ultracentrifuged (150 000g, 30 min at 4°C) to remove oligomeric tubulins. To the supernatants (50 μL) were added 2 mM paclitaxel in DMSO (0.3 μL) to induce microtubule formation, and/or 6 μM actin in modified RB buffer (50 μL) and ApA or its analogues (1−2 μL). After incubation for 30 min at 37°C, samples were ultracentrifuged (150 000g, 37°C, 1 h). Aliquots of the supernatants and precipitates (redissolved in modified RB buffer) were mixed with the same amount of 2× SDS buffer and boiled for 5 min at 95°C. SDS-PAGE was performed using a precast 10% polyacrylamide gel, and the gels were stained with a Quick-CBB kit (Wako).
Molecular Modeling Studies. Molecular modeling studies were performed using the Molecular Operating Environment (MOE) 2014.09 program package (Chemical Computing Group, Inc.), as described previously.
10,30 For docking model studies, all water molecules associated with the actin−ApA complex (PDB: 1WUA) were removed, except for those near the ligand, and all protons on the protein and the ligand were complemented. Conformational searches were performed using the Amber12:EHT force-field with GB/VI Generalized Born 31 implicit solvent electrostatics (D in = 1, D out = 80) and with LowModeMD, 32 in which both the actin and the side-chain moiety (C23−C34) of aplyronines and their synthetic analogues were fixed.
Synthesis and Spectroscopic Data of ApA Analogues. Thioether 9a. To a stirred solution of primary alcohol 9 (7.1 g, 20 mmol) 18 and 5,5′-dithiobis(1-phenyl-1H-tetrazole) (9.3 g, 26 mmol) in dry THF (67 mL) cooled at 0°C was added tri-nbutylphosphine (8.0 mL, 32 mmol), and the resulting solution was stirred at room temperature for 16 h. Water (80 mL) was added, and the resulting mixture was extracted with EtOAc (25 mL × 3). The combined extracts were washed with sat. NaHCO 3 aq and brine, dried with Na 2 SO 4 , and concentrated. The crude material was purified with a SiO 2 column (50 g, hexane/EtOAc = 40/1 to 9/1) to give thioether 9a (9. 5 
Phenyltetrazole Sulfone 10. To a stirred solution of thioether 9a (1.9 g, 3.7 mmol) in dry CH 2 Cl 2 (37 mL) cooled at 0°C were added NaHCO 3 (0.94 g, 11 mmol) and mchloroperoxybenzoic acid (2.1 g, 12 mmol). After being stirred for 24 h at room temperature, the reaction mixture was diluted with sat. Na 2 S 2 O 3 aq (30 mL) at 0°C, stirred for 30 min, and extracted with CH 2 Cl 2 (20 mL × 3). The combined extracts were washed with brine, dried with Na 2 SO 4 , and concentrated. The crude material was purified with a SiO 2 column (50 g, hexane/EtOAc = 40/1 to 1/1) to give phenyltetrazole sulfone 10 (1.9 mg, 96%) as a light yellow oil. 10: R f = 0. + , Δ −2.2 mmu). Olefin 11a. To a stirred solution of phenyltetrazole sulfone 10 (1.9 g, 3.5 mmol) in dry DME (18 mL) cooled at −55°C was added a 1.0 M solution of LHMDS in THF (3.5 mL, 3.5 mmol) dropwise under a nitrogen stream. The mixture was stirred at −55°C for 30 min, then a solution of aldehyde 11 (0.39 g, 1.3 mmol) in DME (2 mL) was added dropwise for 10 min, and the resulting mixture was stirred at −55°C for 2 h and allowed to warm to room temperature for 16 h. After the addition of brine (10 mL) at 0°C, the reaction mixture was extracted with ether (10 mL × 3). The combined extracts were washed with brine, dried with Na 2 SO 4 , and concentrated. The crude material was purified with a SiO 2 column (50 g, hexane/ acetone = 65/1 to 10/1) to give olefin 11a (0.82 g, 100%, E/Z = 1:2) and recovered sulfone 10 (0.94 g) as light yellow oils. + , Δ −2.0 mmu). Diol 11b. A solution of olefin 11a (2.5 g, 4.1 mmol) in dry THF (14 mL) and i-PrOH (5.1 mL) was added in liquid ammonia (10 mL) at −78°C. Calcium (0.49 g, 12 mmol) was added to the solution, and the mixture was stirred at −78°C for 2 h. After the addition of ammonium chloride (4 g) and iron(III) nitrate nonahydrate (0.80 g), the mixture was stirred at −78°C for 1 h and allowed to warm to room temperature for 5 h. The reaction mixture was diluted with water (20 mL) and extracted with ether (10 mL × 3). The combined extracts were washed with brine, dried with Na 2 SO 4 , and concentrated. The crude material was purified with a SiO 2 column (36 g, hexane/acetone = 65/1 to 5/1) to give diol 11b (1.2 g, 69%, E/Z = 1:2) as a colorless oil. 11b: R f = 0. 18 To a stirred solution of diol 11b (1.0 g, 2.3 mmol) in dry DMF (12 mL) cooled at 0°C were added imidazole (0.32 g, 4.6 mmol) and tert-butylchlorodiphenylsilane (0.60 mL, 2.3 mmol). After being stirred for 3 h at room temperature, the reaction mixture was diluted with water (20 mL) and extracted with EtOAc (10 mL × 3). The combined extracts were washed with water and brine, dried with Na 2 SO 4 , and concentrated. The crude material was purified with a SiO 2 column (34 g, hexane/EtOAc = 5/1 to 4/1) to give TBDPS Hemiacetal 12c. A mixture of lactone 12b (38 mg, 50 μmol) in DME (6.2 mL) and 1 M HCl aq (2.5 mL) was stirred for 3 h at room temperature. The resulting mixture was neutralized with sat. NaHCO 3 aq (5 mL) at 0°C and extracted with EtOAc (10 mL × 3). The combined extracts were washed with brine, dried with Na 2 SO 4 , and concentrated. The crude material was purified with a SiO 2 column (1 g, hexane/acetone = 10/1 to 1/1) to give hemiacetal 12c (31 mg, 84%, S/R = 3:1 at C29 DMAla moiety, 2.0:1 diastereomer mixture at C34) as a colorless oil. 
To a stirred solution of hemiacetal 12c (27 mg, 36 μmol) in dry MeOH (2.3 mL) cooled at 0°C was added sodium borohydride (8.1 mg, 0.214 mmol). After being stirred at 0°C for 30 min, the resulting mixture was quenched with acetone (1 mL) and diluted with sat. NH 4 Cl aq (3 mL) and extracted with EtOAc (2 mL × 3). The combined extracts were washed with brine, dried with Na 2 SO 4 , and concentrated. The crude material was purified with two SiO 2 columns (FL60D 0.7 g, hexane/EtOAc = 2:1 to 1:2; FL60D 0.7 g, CHCl 3 /acetone = 5:1 to 1:1) to give diol 13 (25 mg, 91%, S/R = 2.0:1 at C29 DMAla moiety) as a colorless oil. None of the stereoisomers of the C29 DMAla ester after 13 were separable by SiO 2 column chromatography, and thus they were all used as mixtures. and DMAP (25 mg, 0.21 mmol) in dry pyridine (1.7 mL) and acetic anhydride (0.80 mL) was stirred at 40°C for 7 h. The resulting mixture was azeotropically concentrated with toluene. The crude material was purified with a SiO 2 column (10 g, hexane/EtOAc = 10/1 to 1/3) to give acetate 14 (103 mg, quant., S/R = 2.0:1 at C29 DMAla moiety) as a colorless oil. 14: R f = 0. + , Δ −0.6 mmu). Primary Alcohol 14a. To a stirred solution of acetate 14 (28.4 mg, 27.2 μmol) in dry ether (1 ml) was added formic acid (0.7 mL). After being stirred for 1 h at 40°C, the resulting mixture cooled at 0°C was quenched with sat. NaHCO 3 aq (5 mL) and extracted with ether (4 mL × 2). The combined extracts were washed with sat. NaHCO 3 aq and brine, dried with Na 2 SO 4 , and concentrated. The crude material containing primary alcohol and formate was dissolved in MeOH (1.5 mL) and 25% aq NH 3 (0.2 mL). After stirring at room temperature for 20 min, the resulting mixture cooled at 0°C was diluted with brine (5 mL) and extracted with ether (3 mL × 3). The combined extracts were washed with brine, dried with Na 2 SO 4 , and concentrated. The crude material was purified with a SiO 2 column (5 g, hexane/EtOAc = 15/1 to 1/1) to give primary alcohol 14a (20.8 mg, 96%, S/R = 2.0:1 at C29 DMAla moiety) as a colorless oil. 14a: R f = 0. 
mmu).
Aldehyde 15. To a stirred solution of primary alcohol 14a (40 mg, 50 μmol) in dry CH 2 Cl 2 (0.5 mL) were added dry pyridine (0.12 mL) and Dess−Martin periodinane (25 mg, 59 μmol). 21 After being stirred at room temperature for 2 h, the resulting mixture was diluted with a 1:1 mixture of sat. Na 2 S 2 O 3 aq and sat. NaHCO 3 aq (2 mL) at 0°C and extracted with ether (2 mL × 4). The combined extracts were washed with brine, dried with Na 2 SO 4 , and concentrated. The crude material was purified with a SiO 2 column (FL60D 5 g, hexane/ EtOAc = 2/1 to 1/2) to give aldehyde 15 (41 mg, quant., S/R = 2.0:1 at C29 DMAla moiety) as a colorless oil. 22 (360 mg, 1.63 mmol) in dry THF (5.4 mL) and i-PrOH (2 mL) was added in liquid ammonia (4.1 mL) at −78°C. Calcium (0.14 g, 3.6 mmol) was added to the solution, and the mixture was stirred at −78°C for 1 h 20 min. After the addition of ammonium chloride (2 g) and iron(III)nitrate nonahydrate (0.25 g), the mixture was stirred at −78°C for 1 h and allowed to warm to room temperature for 6 h. The reaction mixture was diluted with water (8 mL) and extracted with EtOAc (5 mL × 6). The combined extracts were washed with brine, dried with Na 2 SO 4 , and concentrated to give known diol 17a (0.25 g), which was used for the next step without further purification.
To a stirred solution of the above crude diol 17a (0.25 g) in dry CH 2 Cl 2 (8.3 mL) and 2,2-dimethoxypropane (1.0 mL, 8.0 mmol) was added 10-camphorsulfonic acid (19 mg, 8.2 μmol). After stirring at room temperature for 2.5 h, the resulting mixture was quenched with sat. NaHCO 3 aq (2 mL) and extracted with CH 2 Cl 2 (1 mL × 3). The combined extracts were washed with brine, dried with Na 2 SO 4 , and concentrated. The crude material was purified with a SiO 2 column (12 g, hexane/acetone = 30/1 to 10:1) to give acetonide 17b (280 mg, 99%) as a colorless oil. Aldehyde 17c. To a solution of acetonide 17b (430 mg, 2.53 mmol) in acetone−H 2 O (3:1, 25 mL) were added Nmethylmorpholine N-oxide (593 mg, 5.06 mmol) and a 0.1 M solution of osmium(VIII)oxide in tert-butyl alcohol (1.26 mL, 126 μmol) at 0°C. After stirring at room temperature for 1 h, sodium periodate (1.46 g, 6.8 mmol) was added. After stirring at room temperature for 1 h, the resulting mixture was quenched with sat. Na 2 S 2 O 3 aq (10 mL) and extracted with ether (5 mL × 3). The combined extracts were washed with sat. Na 2 S 2 O 3 aq and brine, dried with Na 2 SO 4 , and concentrated. The crude material was purified with a SiO 2 TMSer Ester 24a. A solution of secondary alcohol 24 (5.3 mg, 5.2 μmol), N,N,O-trimethyl-L-serine (7.7 mg, 52 μmol), and DMAP (7.8 mg, 64 μmol) in dry CH 2 Cl 2 (0.17 mL) was added EDC·HCl (11 mg, 57 μmol). After stirring at room temperature for 2.5 h, the reaction mixture was quenched with sat. NaHCO 3 aq (1 mL) at 0°C and extracted with EtOAc (1 mL × 4). The combined extracts were washed with brine, dried with Na 2 SO 4 , and concentrated. The crude material was purified with SiO 2 column chromatography (FL60D 0. 5 2C), 129.3, 127.7 (4C), 125.4, 112.1, 110.5, 78.8 ApA Analogue 5. TMSer ester 24a (1.2 mg, 1.0 μmol) was dissolved in a 5:3:7 mixture of hydrogen fluoride pyridine, pyridine, and dry THF (0.5 mL) at 0°C. After being stirred for 18 h at room temperature, the reaction mixture was poured into sat. NaHCO 3 aq (2 mL) at 0°C and extracted with EtOAc (2 mL × 4). The combined extracts were washed with brine, dried with Na 2 SO 4 , and concentrated. The crude material was purified with SiO 2 column chromatography (FL60D 0. Bis-TMSer Ester 7. To a solution of ApC analogue 6 (2.2 mg, 3.1 μmol), N,N,O-trimethyl-L-serine (5.3 mg, 36 μmol), and DMAP (4.4 mg, 36 μmol) in dry CH 2 Cl 2 (0.15 mL) was added EDC·HCl (6.3 mg, 33 μmol). After stirring at room temperature for 22 h, the reaction mixture was quenched with sat. NaHCO 3 aq (1 mL) at 0°C and extracted with EtOAc (1 mL × 3). The combined extracts were washed with brine, dried with Na 2 SO 4 , and concentrated. The crude material was purified with a reversed-phase HPLC [Develosil ODS-HG-5 (ϕ 20 × 250 mm), MeOH/20 mM aq NH 4 OAc (75/25), 5 mL/min, UV254 nm, t R 23.8−27.4 min] to give bis-TMSer ester 7 (0.6 mg, 21%, S/R = 1.6:1 at C34 enamide moiety) as a colorless oil. The eluate was freeze-dried, dissolved in water, and freeze-dried again twice to remove remaining ammonium acetate. Analogue 7 was obtained as a mixture of stereoisomers at the C7 TMSer and C29 DMAla ester moieties and was not separable by reversed-phase HPLC. Bioassays were carried out with mixture of stereoisomers. 20 (m, 1H), 4.02 (m, 2H), 3.64 (dd, J = 8.9, 2.8 
